Impact of Body Mass Index, Central Adiposity, and Weight Loss on the Benefits of Tirzepatide in HFpEF: The SUMMIT Trial

What Was Tested

The paper reports a study of Tirzepatide, published as a randomized controlled trial.

In this analysis, the authors compared baseline characteristics and effects of tirzepatide on primary and other endpoints according to baseline obesity severity and distribution, and the researchers explored relationships between degree of weight loss achieved and outcomes.

Why It Was Studied

Effects may differ by baseline obesity severity, distribution, or magnitude of weight loss.

Who Took Part

The study group was 731 patients.

The age groups tagged for this paper are middle-aged adults and older adults, both men and women.

In the SUMMIT trial, 731 patients with NYHA functional class II-IV HFpEF and body mass index (BMI) ≥30 kg/m2 were randomly assigned to tirzepatide (n = 364) or placebo (n = 367).

Relationships between changes in BW and waist circumference (WC) on treatment with tirzepatide and changes in key endpoints also were evaluated.

How the Study Was Run

In design terms this was a randomized, double-blind and placebo-controlled study.

Because people in this Tirzepatide study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Blinding on both sides kept the patients and researchers unaware of who received Tirzepatide.

Some patients received a placebo instead of Tirzepatide, giving a reference point.

Key secondary outcomes included changes in 6-minute walk distance (6MWD), C-reactive protein (CRP), and body weight (BW) at 52 weeks.

In this secondary analysis, primary and secondary endpoints were analyzed based on obesity severity (BMI) and distribution (waist-height ratio [WHR]).

Time-to-event endpoints were analyzed with the use of a Cox regression model, and continuous endpoints were assessed with the use of a mixed-effects model for repeated measures.

What Was Measured

The subject headings attached to it are Body Mass Index, Heart Failure, Weight Loss, Tirzepatide, Stroke Volume, Adiposity and Obesity, Abdominal.

Author keywords: HFpEF, clinical trial, pathophysiology and visceral fat.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Tirzepatide in 731 patients.

With several hundred people or more, it is a fairly large study for this kind of research.

Its findings take up roughly 10 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2025 (Journal of the American College of Cardiology), a journal based in United States.

More context: the Tirzepatide compound page, all human trials.